

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

SECTION 1: Identification of the substance/mixture and of the company/undertaking**1.1 Product identifier**

Trade name : Orbifloxacin Solid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Veterinary product

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
20 Spartan Road
1619 Spartan, South Africa

Telephone : +27119239300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification**2.1 Classification of the substance or mixture****Classification (REGULATION (EC) No 1272/2008)**

Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child.

2.2 Label elements**Labelling (REGULATION (EC) No 1272/2008)**

Hazard pictograms :



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protec-

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Orbifloxacin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients**3.2 Mixtures****Components**

| Chemical name | CAS-No. EC-No. Index-No. Registration number | Classification | Concentration (% w/w) |
|---------------|---|----------------|--------------------------|
| Orbifloxacin | 113617-63-3 | Repr. 2; H361d | >= 3 - < 10 |

For explanation of abbreviations see section 16.

SECTION 4: First aid measures**4.1 Description of first aid measures**

- | | | |
|----------------------------|---|---|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air. Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water. |

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Suspected of damaging the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures**5.1 Extinguishing media**

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures**6.1 Personal precautions, protective equipment and emergency procedures**

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage**7.1 Precautions for safe handling**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection**8.1 Control parameters****Occupational Exposure Limits**

| Components | CAS-No. | Value type (Form of exposure) | Control parameters | Basis |
|--------------|-------------|-------------------------------|--------------------|----------|
| Orbifloxacin | 113617-63-3 | TWA | 0.2 mg/m3 (OEB 2) | Internal |

8.2 Exposure controls**Engineering measures**

Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material : Chemical-resistant gloves

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

| | | |
|--------------------------|---|--|
| Skin and body protection | : | Work uniform or laboratory coat. |
| Respiratory protection | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. |
| Filter type | : | Particulates type (P) |

SECTION 9: Physical and chemical properties**9.1 Information on basic physical and chemical properties**

| | | |
|--|---|---|
| Appearance | : | powder |
| Colour | : | No data available |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapour pressure | : | No data available |
| Relative vapour density | : | No data available |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) | : | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | No data available |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| Viscosity | : | |
| Viscosity, kinematic | : | No data available |

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

9.2 Other information

Molecular weight : No data available

Particle size : No data available

SECTION 10: Stability and reactivity**10.1 Reactivity**

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information**11.1 Information on toxicological effects**

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:**Orbifloxacin:**

Acute oral toxicity : LD50 (Rat): > 3.000 mg/kg
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2.000 mg/kg
Remarks: No mortality observed at this dose.

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Components:**Orbifloxacin:**

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Orbifloxacin:**

Species : Rabbit
Method : Draize Test
Result : Mild eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Orbifloxacin:**

Test Type : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:**Orbifloxacin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal

Test Type: Mouse Lymphoma
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intraperitoneal injection
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**Orbifloxacin:**

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Reproductive toxicity

Suspected of damaging the unborn child.

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

Components:**Orbifloxacin:**

- Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: NOAEL: 50 mg/kg body weight
Early Embryonic Development: NOAEL: 50 mg/kg body weight
Result: No adverse effects
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Embryo-foetal toxicity: LOAEL: 333 mg/kg body weight
Result: No teratogenic effects, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses
- Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
General Toxicity Maternal: NOAEL: 20 mg/kg body weight
Embryo-foetal toxicity: NOAEL: 60 mg/kg body weight
Result: No effects on early embryonic development, Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, Reduced maternal body weight gain
- Test Type: Development
Species: Dog
Application Route: Oral
Developmental Toxicity: LOAEL: 2,5 mg/kg body weight
Result: Effects on postnatal development, Skeletal malformations
- Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity**Components:****Orbifloxacin:**

- Species : Rat
NOAEL : 20 mg/kg
LOAEL : 80 mg/kg
Application Route : Oral
Exposure time : 3 Months

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

Target Organs : Testis, Liver, Kidney, spleen

Species : Mouse
NOAEL : 80 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 3 Months

Species : Juvenile dog
NOAEL : 50 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 14 Days
Target Organs : Heart, Bone
Symptoms : Gastrointestinal disturbance
Remarks : mortality observed

Species : Juvenile dog
NOAEL : 2 mg/kg
LOAEL : 3 mg/kg
Application Route : Oral
Exposure time : 90 Days
Target Organs : Bone
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 37,5 mg/kg
Application Route : Oral
Exposure time : 30 Days

Species : Cat
NOAEL : 7,5 mg/kg
LOAEL : 22,5 mg/kg
Application Route : Oral
Exposure time : 1 Months
Symptoms : Gastrointestinal disturbance

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Orbifloxacin:**

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitisation.

SECTION 12: Ecological information**12.1 Toxicity**

No data available

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

No data available

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects**Product:**

Endocrine disrupting potential : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations**13.1 Waste treatment methods**

| | |
|------------------------|---|
| Product | : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. |
| Contaminated packaging | : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product. |

SECTION 14: Transport information**14.1 UN number**

| | |
|------|-------------------------------------|
| ADN | : Not regulated as a dangerous good |
| ADR | : Not regulated as a dangerous good |
| RID | : Not regulated as a dangerous good |
| IMDG | : Not regulated as a dangerous good |
| IATA | : Not regulated as a dangerous good |

14.2 UN proper shipping name

| | |
|-----|-------------------------------------|
| ADN | : Not regulated as a dangerous good |
|-----|-------------------------------------|

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

| | | |
|-------------|---|-----------------------------------|
| ADR | : | Not regulated as a dangerous good |
| RID | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA | : | Not regulated as a dangerous good |

14.3 Transport hazard class(es)

| | | |
|-------------|---|-----------------------------------|
| ADN | : | Not regulated as a dangerous good |
| ADR | : | Not regulated as a dangerous good |
| RID | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA | : | Not regulated as a dangerous good |

14.4 Packing group

| | | |
|-------------------------|---|-----------------------------------|
| ADN | : | Not regulated as a dangerous good |
| ADR | : | Not regulated as a dangerous good |
| RID | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA (Cargo) | : | Not regulated as a dangerous good |
| IATA (Passenger) | : | Not regulated as a dangerous good |

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information**15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**

The components of this product are reported in the following inventories:

| | | |
|-------|---|----------------|
| AICS | : | not determined |
| DSL | : | not determined |
| IECSC | : | not determined |

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H361d : Suspected of damaging the unborn child.

Full text of other abbreviations

Repr. : Reproductive toxicity

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 2

H361d

Classification procedure:

Calculation method

Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 30.09.2023 |
| 3.2 | 14.04.2025 | 801091-00018 | Date of first issue: 15.07.2016 |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

ZA / EN